Latest Breaking News On - Mesoblast inc - Page 2 : comparemela.com

Dr. Grossman brings over 20 years of drug development expertise having held senior executive leadership positions in large and small pharmaceutical companies leading the development and FDA approval of numerous multi-billion dollar blockbuster drugs addressing significant unmet medical needs particularly across CNS disorders. Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He served as President and Chief Medical Officer at Glenmark Pharmaceuticals (BSE: 532296) as well as Chief Medical Officer at Mesoblast, Inc. (NASDAQ: MESO). Dr. Grossman is Board-Certified in Psychiatry and a Fellow of the American Psychiatric Association and was a Fellow at the National Institutes of Health (NIH). He has held several academic appointments and authored numerous scientific publications. Dr. Grossman will succeed Dr. Hepner, who is transitioning his position due to personal reasons, but will remain committed to Coya as Clinical a

United statesEli lillyAdrian hepnerHowardh bermanFred grossmanMesoblast incBristol myers squibbCoya therapeutics incGlenmark pharmaceuticalsCoya therapeuticsChief medicalAmyotrophic lateral sclerosisChief medical officer